Search research articles
Contact Us
Filters
Showing results (411-420 of 509) with videos related to
Page
of 51
Sort By:
Cancers
|
July 24, 2021
Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital Database
Christelle de la Fouchardière, Mustapha Adham, Anne-Marie Marion-Audibert, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 31, 2024
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas
Ondine Becker, Alice Durand, Marion Chevrier, et al.
The Lancet. Oncology
|
July 10, 2023
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial
Jean-Yves Blay, Sylvie Chevret, Axel Le Cesne, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Gynecologic Oncology
|
October 4, 2021
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
Elizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, et al.
Gynecologic Oncology
|
July 23, 2021
Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database
Alexandre De Nonneville, Christophe Zemmour, Sophie Frank, et al.
The Lancet. Oncology
|
June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Nature Communications
|
January 6, 2026
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial
Isabelle Ray-Coquard, Marie-Christine Kaminsky-Forrett, Ryotaro Ohkuma, et al.
JCO Precision Oncology
|
January 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial
Félix Blanc-Durand, Benoit You, Yahia Adnani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium
Nicole Concin, Ioana Braicu, Pierre Combe, et al.
Page
of 51
Search research articles
Search
Showing results (411-420 of 509) with videos related to
Sort By:
Page
of 51
Cancers
|
July 24, 2021
Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital Database
Christelle de la Fouchardière, Mustapha Adham, Anne-Marie Marion-Audibert, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 31, 2024
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas
Ondine Becker, Alice Durand, Marion Chevrier, et al.
The Lancet. Oncology
|
July 10, 2023
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial
Jean-Yves Blay, Sylvie Chevret, Axel Le Cesne, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Gynecologic Oncology
|
October 4, 2021
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
Elizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, et al.
Gynecologic Oncology
|
July 23, 2021
Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database
Alexandre De Nonneville, Christophe Zemmour, Sophie Frank, et al.
The Lancet. Oncology
|
June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Nature Communications
|
January 6, 2026
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial
Isabelle Ray-Coquard, Marie-Christine Kaminsky-Forrett, Ryotaro Ohkuma, et al.
JCO Precision Oncology
|
January 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial
Félix Blanc-Durand, Benoit You, Yahia Adnani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium
Nicole Concin, Ioana Braicu, Pierre Combe, et al.
Page
of 51